Mortality Rates in Dialysis Centers

Expected Mortality Benchmarks

The American Journal of Kidney Diseases reports that annual mortality for hemodialysis patients in the United States ranges from 17-20%, with the HEMO Study reporting 17% and general U.S. data showing 20% per year 1
For elderly patients (≥70 years), first-year mortality approaches 20% 2
Three-year and five-year survival rates are only 55% and 40% respectively, even with dialysis 3
Post-acute myocardial infarction, dialysis patients face approximately 75% mortality within 2 years 4

Japanese dialysis centers achieve annual mortality rates below 10%, suggesting substantial room for improvement in U.S. outcomes 1
This survival advantage persists even after adjusting for patient selection and comorbidity differences through DOPPS analyses 1
Genetic factors may partially explain Asian patients' enhanced survival, whether treated in the U.S. or Japan 1

Cardiovascular disease accounts for the majority of deaths, with acute coronary syndromes carrying particularly poor prognosis 4
Cerebrovascular accidents and other cardiac diseases beyond coronary artery disease contribute significantly 5

The minimum adequate single-pool Kt/V of 1.2 for thrice-weekly dialysis must be maintained, though U.S. centers average 1.52 1
Suboptimal dialysis doses adversely affect patient survival, particularly in adults with ischemic cardiac disease or left ventricular dysfunction 5

Arteriovenous fistulas provide superior one-year survival (84%) compared to grafts (78.2%) and catheters (69.6%) 2

Treat acute coronary syndromes identically to the non-dialysis population, including percutaneous coronary intervention, CABG, antiplatelet agents, beta-blockers, and lipid-lowering agents 4
For ST-elevation MI, emergent PCI is preferred over thrombolytic therapy due to increased hemorrhagic risk in dialysis patients 4
Implement post-MI prophylactic care including aspirin, beta-blockers, and ACE inhibitors, which improve the otherwise 75% two-year mortality 4

Monitor and maintain adequate dialysis dose with target URR ≥65% or Kt/V ≥1.2 for thrice-weekly treatments 1
Ensure proper volume control through adequate ultrafiltration and sodium restriction 1
Consider ultrapure water and alternative therapies (hemofiltration, daily dialysis) for high-risk patients 1

Target interdialytic home blood pressure measurements rather than pre/post-dialysis readings, as these better predict mortality 6
Achieve dry weight through progressive ultrafiltration, which can reduce systolic/diastolic BP by 6.9/3.1 mmHg 6
Use renin-angiotensin system blockers as first-line antihypertensive agents 6

Avoid relying solely on pre-dialysis or post-dialysis blood pressure measurements, as these correlate poorly with interdialytic ambulatory readings and mortality risk 6
Do not withhold standard post-MI therapies due to dialysis status; retrospective studies show protective effects despite lack of randomized trials in dialysis populations 4
Recognize that low blood pressure in dialysis patients may paradoxically indicate higher mortality risk due to underlying cardiac dysfunction, not adequate BP control 6
Inadequate dialysis directly causes at least 10% of technique failures and transfers to alternative modalities 5